Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • ROOMS:

Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast

By: Newsfile

Phoenix, Arizona--(Newsfile Corp. - July 28, 2022) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Chairman, CEO and President of the Company, William Hartman, joined Stock Day host Sever Copley.

Hartman began the interview by updating listeners on the Company's latest developments. "We have been a pink sheet company," explained Hartman. "We filed the Form-10 to be uplisted to the OTCQB index and become fully-reporting in May. In June, we received questions back from the SEC," he continued. "Our response to the questions is in process and will be screened and audited, then will be sent back to the SEC."

"We have four existing issued patents, and we have 22 pending patents," shared Hartman. "Our strategy is to remain very broad and come out with a lot of potential applications of our key patented technology, which is to work with bodily fluids extracorporeally to eradicate disease," he said, noting that the Company's technology does not require any injected or ingested drugs, and therefore eliminates side-effects from medications, a major cause of pain, suffering and even death.

"We remove from bodily fluids the inflammatory cytokines, antigens, etc. that cause disease, and we eradicate these using our patented extracorporeal process," continued Hartman, adding that this includes blood, and cerebrospinal, fluid. "Then we return the purified bodily fluids back into the patient. That is huge, that is unique, and revolutionary, and nobody else is doing this."

Copley then asked about the progress of the Company's government contract for the treatment of traumatic brain injury and neurological diseases. Hartman said. "We met with the Department of Defense and then Congressman Mike Kelly, who stated he is very interested in helping us forward this technology."

"Your technology takes a high caliber of skill; how have you continued to build this level of expertise?," asked Copley. "Everyone we've hired, I have personally interviewed," said Hartman. "We have secured the services of the brilliant Dr. Shawn Chen of Arizona State University, who develops antibodies and conjoins metallic nanoparticles to them through a proprietary process such that the antibody does not lose affinity for the target disease antigen. He then sends the combined antibody-nanoparticle mixture to Youngstown State University where the conjoined antibody is introduced to the antigen infected bodily fluid and eradicated through exposure to tuned laser energy."

"We have been successful in eliminating all 11 selected target antigens associated with neurodegenerative diseases," shared Hartman. "We have also worked on eliminating several strains of E. coli, which can lead to meningitis and blood sepsis which kills thousands of people each year."

"What does the future look like for the Halberd Corporation?," asked Copley. "We have expanded our extracorporeal research into developing cancer antibodies," said Hartman. "We are starting cancer research, initially focusing on PD-1 and PDL-1 antigens. We will follow this by working to eliminate BTLA and CTLA-4 antigens. This covers most cancer types. Because of our promising anticancer research developments, we are forming a dedicated cancer subsidiary as well as a COVID subsidiary. Both of these subsidiaries could eventually be spun off to the benefit of existing Halberd stockholders."

"We are planning to conduct animal tests at Mississippi State University," continued Hartman. "We are also beginning work on a nasal spray which could be administered to victims of traumatic brain injury," he said, adding that the spray is designed to reduce or prevent the expression of inflammatory neurotransmitters as a result of traumatic brain injury.

To close the interview, Hartman elaborated on the Company's potential within the pharmaceutical industry, as well as the potential for government contracts, which would significantly impact the Company's growth. He also encouraged listeners and shareholders to keep up-to-date on the Company's current projects and upcoming announcements by signing up through their website at

To hear the entire interview with William Hartman, follow the link to the podcast here:

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About Halberd Corporation

Halberd Corporation (OTC Pink: HALB) is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April, 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions our readers that statements and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photography by Christophe Tomatis
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.